Escherichia coli outer membrane vesicles targeting tlr2 receptor and construction method thereof

By displaying the fusion protein ClyA-HLYV formed by HLYVSPW peptide and ClyA protein on the surface of E. coli outer membrane vesicles, outer membrane vesicles targeting the TLR2 receptor were constructed, solving the problems of low tumor targeting and drug delivery efficiency in traditional breast cancer treatment, and achieving rapid and efficient targeted therapy.

CN121379905BActive Publication Date: 2026-07-07THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF TCM
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF TCM
Filing Date
2025-09-15
Publication Date
2026-07-07

AI Technical Summary

Technical Problem

Among existing breast cancer treatments, traditional chemotherapy drugs lack tumor targeting, leading to severe toxic side effects. The prognosis for metastatic and recurrent breast cancer is not ideal. There is an urgent need to develop novel targeted drug delivery systems that combine high tumor killing efficiency, low systemic toxicity, and excellent biocompatibility.

Method used

We constructed E. coli outer membrane vesicles (HLYV-OMVs) targeting the TLR2 receptor. By displaying the fusion protein ClyA-HLYV formed by HLYVSPW peptide and ClyA protein on the surface of E. coli outer membrane vesicles, we achieved specific recognition of the TLR2 receptor and drug delivery.

Benefits of technology

HLYV-OMVs not only retain the ability to specifically recognize the TLR2 receptor on the surface of breast cancer cells, but also have the potential for rapid drug delivery, significantly accelerating the onset of the effect after HLYV binds to the receptor, solving the problem of the long onset time of HLYV single peptides, and providing a basis for highly efficient targeted therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121379905B_ABST
    Figure CN121379905B_ABST
Patent Text Reader

Abstract

The application provides an E. coli outer membrane vesicle targeting TLR2 receptor and a construction method thereof, and relates to the technical field of biological medicine. The application first constructs a ClyA-HLYV fusion protein, and successfully obtains a recombinant plasmid ClyA-HLYV-pGEX-6P-1 stably expressing the fusion protein through genetic engineering technology, and induces endogenous expression of the fusion protein in an E. coli W3110 strain, to prepare a targeted bacterial outer membrane vesicle (HLYV-OMVs) expressing the ClyA-HLYV fusion protein on the surface. The HLYV-OMVs prepared by the application not only retain the specific recognition ability of HLYV to the surface TLR2 receptor of breast cancer cells, but also have the potential to encapsulate drugs, realizing the dual functions of targeted recognition and drug delivery. In addition, the HLYV-OMVs effectively solve the key problem of long-acting time of HLYV single peptide in targeted application, have good stability, significantly accelerate the effect starting speed after HLYV combines with the receptor, and lay an important foundation for efficient targeted treatment of tumors.
Need to check novelty before this filing date? Find Prior Art